Nifekalant
- Generic Name
- Nifekalant
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H27N5O5
- CAS Number
- 130636-43-0
- Unique Ingredient Identifier
- 5VZ7GZM43E
- Background
Nifekalant is under investigation in clinical trial NCT03855826 (Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection).
- Indication
用于其它抗心率失常药无效或不耐受的严重的室性心率失常、室颤患者的治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Nifekalant Versus Amiodarone in New-Onset Atrial Fibrillation After Cardiac Surgery
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Beijing Anzhen Hospital
- Target Recruit Count
- 274
- Registration Number
- NCT05169866
- Locations
- 🇨🇳
Beijing Anzhen Hospital, Beijing, China
Comparison of Efficacy and Safety of Different Doses of Nifekalant Instant Cardioversion of Persistent Atrial Fibrillation During Radiofrequency Ablation
- First Posted Date
- 2019-12-24
- Last Posted Date
- 2019-12-24
- Target Recruit Count
- 300
- Registration Number
- NCT04209959
- Locations
- 🇨🇳
The Second Afiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath